- ￥295 - 4738
- MedChemExpress(MCE)
- 美国
- HY-10977
- 2025年12月05日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 技术资料
- 保存条件：
Powder: -20°C, 3 years; 4°C, 2 years.In solvent: -80°C, 6 months; -20°C, 1 month.
- 英文名：
AV-951; KRN951
- 库存：
货期：1-2天
- 供应商：
MedChemExpress LLC
- 规格：
10 mM * 1 mL/1 mg/5 mg/10 mg/50 mg/100 mg
| 规格： | 10 mM * 1 mL | 产品价格： | ￥715.0 |
|---|---|---|---|
| 规格： | 1 mg | 产品价格： | ￥295.0 |
| 规格： | 5 mg | 产品价格： | ￥650.0 |
| 规格： | 10 mg | 产品价格： | ￥1000.0 |
| 规格： | 50 mg | 产品价格： | ￥3100.0 |
| 规格： | 100 mg | 产品价格： | ￥4738.0 |
MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。
Tivozanib
CAS No. : 475108-18-0
MCE 国际站：Tivozanib
产品活性：Tivozanib (AV-951; KRN951) 是一种有效的、选择性的、具有口服活性的 VEGFR 酪氨酸激酶 抑制剂，对 VEGFR-1、VEGFR-2、VEGFR-3的 IC50 值分别为 0.21、0.16、0.24 nM。Tivozanib 抑制肿瘤组织中的血管生成和血管通透性，并显示出抗肿瘤活性。Tivozanib 具有研究转移性肾细胞癌 (RCC) 的潜力。
研究领域：Protein Tyrosine Kinase/RTK
作用靶点：VEGFR
In Vitro: Tivozanib inhibits the phosphorylation of VEGFR-1, VEGFR-2 and VEGFR-3.
In Vivo: Tivozanib (1 mg/kg; p.o.; 14 days) suppresses the development of CNV lesions and leds to a significant regression of established CNV, reducing the affected areas by 67.7%.
相关产品：Covalent Screening Library Plus | Drug Repurposing Compound Library Plus | FDA-Approved Drug Library Plus | FDA-Approved Drug Library Mini | Bioactive Compound Library Plus | Kinase Inhibitor Library | Protein Tyrosine Kinase Compound Library | FDA-Approved Drug Library | Anti-Cancer Compound Library | Drug Repurposing Compound Library | Covalent Screening Library | Differentiation Inducing Compound Library | Reprogramming Compound Library | Orally Active Compound Library | FDA Approved & Pharmacopeial Drug Library | Anti-Breast Cancer Compound Library | Anti-Lung Cancer Compound Library | Anti-Pancreatic Cancer Compound Library | Anti-Blood Cancer Compound Library | Anti-Obesity Compound Library | Angiogenesis-Related Compound Library | Targeted Diversity Library | Anti-Liver Cancer Compound Library | Anti-Colorectal Cancer Compound Library | EMA-Approved Drug Library | FDA-Approved Anticancer Drug Library | Human Metabolite Library | Anti-Prostate Cancer Compound Library | Anti-Pulmonary Fibrosis Compound Library | Off-patent Drug Library | Membrane Protein-targeted Compound Library | Membrane Receptor-targeted Compound Library | Highly Selective Inhibitors Library | Cytokine Inhibitors Library | Sorafenib | Lenvatinib | Sunitinib | Regorafenib | Nintedanib | Bevacizumab | Semaxinib | Cabozantinib | Ponatinib | Axitinib | Midostaurin | Chloramphenicol | Pazopanib | PD173074 | 5Z-7-Oxozeaenol | Linifanib | Tanshinone IIA | Vandetanib | Foretinib | SU 5402 | Fruquintinib | SPHINX31 | Ripretinib | E3330 | Dovitinib | GW806742X | Sitravatinib
热门产品线：重组蛋白 | 化合物库 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物
Trending products：Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Dye Reagents | PROTAC | Isotope-Labeled Compounds
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
技术资料暂无技术资料 索取技术资料
